# NCT05316155 (NCT05316155)

> Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05316155
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Non-Muscle Invasive Bladder Neoplasms
- Interventions: Erdafitinib Intravesical Delivery System
- Enrollment: 235
- Primary outcome: Parts 1 to 3: Number of Participants with Adverse Events (AEs)
- Primary outcome: Parts 1 to 3: Number of Participants with AEs by Severity
- Primary outcome: Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
- Primary outcome: Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)

## Indexed commentary on NCT05316155 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05316155